Gene therapy
News
May 17, 2025
Duchenne Muscular Dystrophy: Genethon presents Two-Year consolidated results of the GNT0004 Gene Therapy
(read more)
May 17, 2025
Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025
(read more)
May 16, 2025
New advances in the treatment of ALS: Genethon's DNA bank involved in the trial
(read more)
May 13, 2025
Genethon arrives in force at ASGCT 2025 with 12 communications, including 5 oral presentations
(read more)
March 20, 2025
High-throughput screening identification of two molecules as potential approaches for treating a form of limb-girdle muscular dystrophy (LGMD-R2)
(read more)
March 7, 2025
Gene therapy for sickle cell anemia: Genethon has contributed its expertise to the design of an innovative vector
(read more)
February 27, 2025
Genethon Celebrates Rare Disease Day by Highlighting New Technologies to Advance Gene Therapies and Bring Hope to Millions of Patients Worldwide
(read more)
January 23, 2025
Genethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies
(read more)
December 19, 2024
Ana Buj Bello, winner of the Léon Baratz Prize, Docteur Darolles for her research on a gene therapy to cure myotubular myopathy
(read more)
December 3, 2024
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
(read more)
November 19, 2024
Genethon Presents Positive Initial Results from a Phase 1/2/3 Trial of its Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy in Chicago
(read more)
October 21, 2024
Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31st Annual Congress October 22 – 25, 2024 in Rome, Italy
(read more)
September 17, 2024
Genethon and Samabriva strengthen their partnership to develop of a cost-effective plant-based AAV manufacturing process for greater patient access to gene therapies.
(read more)
September 12, 2024
Genethon Announces Publication in Nature Communications of a Next-Generation Gene Therapy Vector for Muscle Diseases, Using AI Predictive Methodology to Improve Efficacy and Safety
(read more)
September 6, 2024
Marking World Duchenne Muscular Dystrophy Day, Genethon Reaffirms Its Commitment to Helping Patientsfor 35 years and Provides an Update on Its PromisingGene Therapy Drug Candidate for This Fatal Disease
(read more)
May 3, 2024
Genethon’s Scientists Featured in Multiple Presentations at American Society of Gene & Cell Therapy Annual Meeting May 7-11, 2024, in Baltimore, MD
(read more)
Serving the public interest
Our mission: Conception, clinic and preclinic development of drugs of genic therapy for rare diseases
Our goal: Providing these innovative treatments to the sick
Our science
Act for the general interest
Our mission: the design and preclinical and clinical development of gene therapy drugs for rare diseases.
Our objective: to make these innovative treatments available to patients.
